Ongoing work in her group includes: • Characterization of the antibody repertoire and allelic diversity in different populations. This work supports the identification of signatures associated with protection, disease or vaccine response outcomes and will contribute towards providing region-specific allelic variants, thus improving the relevance of universal databases to our setting. • Assessing antigen-specific B cell precursor frequencies to inform rational vaccine strategies. This work provides predictive data that can guide the inclusion of target populations for clinical trials aiming to prime or boost specific precursor responses. • Established a platform for non-conventional immunogenicity analysis to inform the iterative processes for rational vaccine approaches. Specifically, we are using this platform to support immunogenicity endpoint analysis for germline targeting vaccine approaches. • Assessment of environmental exposures and regulatory mechanisms that may impact vaccination response. This work will inform the observed vaccine response heterogeneity between different settings and populations. • Characterization of HIV diversity and evolution in Africa and its impact on bnAbs currently informing immunogen design or targeted for therapeutic intervention. This work will inform if the bnAbs in use are appropriate for the current epidemic. In addition, it will provide avenues to guide the engineering of potentially more potent bnAbs for therapeutics or to guide new generation immunogens.